AXSOME THERAPEUTICS, INC. (AXSM) Quick Ratio
- Quick ratio · latest quarter: Value (m); Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | (m) | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | (m) | Cash and Cash Equivalents, at Carrying Value · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 460.45M USD | Liabilities, Current |
| Cash and equivalents | 319.85M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 277.46M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 37.88M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $460.45M | $319.85M | (m) | $277.46M | $37.88M | (m) |
| 2026-03-31 | (m) | $439.21M | $305.11M | (m) | $251.06M | $31.52M | (m) |
| 2025-12-31 | (m) | $378.84M | $322.93M | (m) | $224.46M | $27.94M | (m) |
| 2025-09-30 | (m) | $360.29M | $325.27M | (m) | $196.51M | $23.77M | (m) |
| 2025-06-30 | (m) | $342.10M | $303.02M | (m) | $198.82M | $18.44M | (m) |
| 2025-03-31 | (m) | $243.91M | $300.91M | (m) | $161.40M | $16.32M | (m) |
| 2024-12-31 | (m) | $230.10M | $315.35M | (m) | $142.00M | $15.73M | (m) |
| 2024-09-30 | (m) | $196.19M | $327.34M | (m) | $124.10M | $14.27M | (m) |
| 2024-06-30 | (m) | $186.57M | $315.66M | (m) | $120.34M | $15.22M | (m) |
| 2024-03-31 | (m) | $144.05M | $331.44M | (m) | $101.43M | $15.58M | (m) |
| 2023-12-31 | (m) | $138.85M | $386.19M | (m) | $94.82M | $15.13M | (m) |
| 2023-09-30 | (m) | $114.66M | $416.56M | (m) | $78.42M | $9.98M | (m) |
| 2023-06-30 | (m) | $114.97M | $437.11M | (m) | $67.41M | $9.25M | (m) |
| 2023-03-31 | (m) | $100.65M | $246.51M | (m) | $44.79M | $7.94M | (m) |
| 2022-12-31 | (m) | $96.56M | $200.84M | (m) | $37.70M | $4.32M | (m) |
| 2022-09-30 | (m) | $60.28M | $227.52M | (m) | $20.30M | $2.10M | (m) |
| 2022-06-30 | (m) | $42.57M | $73.39M | (m) | $16.17M | $10.32M | (m) |
| 2022-03-31 | (m) | $24.55M | $84.71M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $23.07M | $86.47M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $24.71M | $114.62M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $22.86M | $141.22M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $21.68M | $164.66M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $23.44M | $183.88M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $20.34M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $23.00M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $26.10M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $24.49M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $18.51M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $13.07M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $7.71M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $10.82M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $10.94M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $9.53M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $9.42M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $12.18M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $8.40M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $8.21M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $8.36M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $7.17M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $6.74M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $5.10M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $3.91M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $2.63M | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |